Overview

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
PureTech
Treatments:
Pirfenidone